NASDAQ$FLGT
Fulgent Genetics Inc. · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Fulgent Genetics reported first quarter results exceeding expectations for both core revenue and COVID-19 revenue.
Fulgent Genetics reported a revenue of $320.3 million for Q1 2022, with core revenue excluding COVID-19 NGS testing growing 59% year-over-year to $25.1 million. The company has raised its full-year revenue outlook to $660 million and core revenue outlook to $180 million.
- Revenue totaled $320.3 million.
- Core Revenue excluding COVID-19 NGS testing grew 59% year-over-year to $25.1 million.
- Full year revenue outlook raised to $660 million from previously announced $600 million.
- Full year core revenue outlook raised to $180 million from previously announced $175 million.
Headline financials
Revenue & EPS history
Fulgent · Revenue · Quarterly
$320M
Revenue by segment
Fulgent · $25.1M total across 1 segment · Q1 2022
- Core Revenue$25.1M—100.0%
Forward guidance
For the second quarter of 2022, Fulgent Genetics expects total revenue of approximately $125 million and core revenue of approximately $40 million, representing growth of 78% year-over-year. For the full year 2022, the company now expects total revenue of approximately $660 million and core revenue of approximately $180 million, with Non-GAAP income of approximately $6.00 per share.
Tailwinds
- Total Revenue of approximately $125 million for Q2 2022.
- Core Revenue of approximately $40 million for Q2 2022, representing growth of 78% year-over-year.
- Total Revenue of approximately $660 million for the full year 2022.
- Core Revenue of approximately $180 million for the full year 2022.
- Non-GAAP income of approximately $6.00 per share for the full year 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
-2.5%
Avg return
Earnings day
-0.5%
Avg return
5 days after
-1.3%
Avg return
30 days after
37%
15 / 41 earnings
Positive
+38.3%
Q3 2019
Best reaction
-38.1%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -7.0% | -1.8% | +19.2% | |
| Q4 2025 | -38.1% | -43.5% | -37.0% | |
| Q3 2025 | +18.3% | +30.3% | +24.6% | |
| Q1 2025 | +18.7% | +8.1% | +20.1% | |
| Q4 2024 | -1.5% | +6.1% | +8.7% | |
| Q3 2024 | -9.0% | -16.3% | -8.8% | |
| Q2 2024 | +0.4% | -0.3% | -4.3% | |
| Q1 2024 | +1.2% | +0.1% | -2.8% | |
| Q4 2023 | -11.5% | -6.8% | -14.8% | |
| Q3 2023 | +14.0% | +11.1% | +15.5% | |
| Q2 2023 | -15.4% | -18.1% | -18.6% | |
| Q1 2023 | +16.1% | +23.4% | +41.4% | |
| Q4 2022 | -2.5% | +3.3% | -9.1% | |
| Q3 2022 | -8.6% | +3.3% | -2.4% | |
| Q2 2022 | -4.9% | -20.4% | -33.9% | |
| Q1 2022 | +4.4% | -4.1% | -1.6% | |
| Q4 2021 | -1.3% | +0.1% | -2.1% | |
| Q3 2021 | -1.1% | +10.5% | +4.3% | |
| Q2 2021 | -8.0% | -10.9% | -15.2% | |
| Q1 2021 | +3.9% | -2.5% | +2.6% | |
| Q4 2020 | -0.5% | +18.1% | +8.3% | |
| Q3 2020 | -17.0% | +6.9% | +20.0% | |
| Q2 2020 | +27.2% | +26.1% | +13.2% | |
| Q1 2020 | -21.0% | +3.9% | +10.3% | |
| Q4 2019 | -32.3% | -42.6% | -29.1% | |
| Q3 2019 | +38.3% | +68.1% | +26.0% | |
| Q2 2019 | +31.9% | +45.4% | +46.7% | |
| Q1 2019 | -15.8% | -16.5% | -11.3% | |
| Q4 2018 | +9.6% | +7.6% | +29.3% | |
| Q3 2018 | +6.9% | +12.3% | +2.8% | |
| Q2 2018 | -0.8% | -4.9% | -17.9% | |
| Q1 2018 | -0.3% | -2.3% | -4.9% | |
| Q4 2017 | -9.1% | -20.9% | -15.6% | |
| Q3 2017 | +0.4% | -4.0% | +0.9% | |
| Q2 2017 | -15.6% | -9.9% | -16.4% | |
| Q1 2016 | -31.1% | -30.0% | -53.4% | |
| Q1 2017 | -33.1% | -29.4% | -53.9% | |
| Q2 2016 | -3.8% | -9.0% | -7.5% | |
| Q4 2016 | +1.1% | -4.2% | -2.9% | |
| Q4 2015 | -1.6% | -1.7% | +8.2% | |
| Q3 2016 | -3.1% | -4.1% | +9.5% | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro